A Randomized, Multiple-dose, Multicenter, Comparative Parallel Study To Evaluate The Efficacy, Safety And Pharmacokinetic Characteristics Of Intravenous Infusion Of Rituximab (Hetero) And Reference Medicinal Product (Rituximab, Roche) In Indian Patients Of Non-Hodgkin's Lymphoma (HERILY Study)
Latest Information Update: 02 Jun 2023
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms HERILY
- Sponsors Hetero Drugs
- 01 Jun 2023 Primary endpoint has been met (Overall Response rate (ORR) by International Working Group (IWG) response criteria at the end of cycle 6) , according to Cancer Chemotherapy and Pharmacology.
- 01 Jun 2023 Results published in the Cancer Chemotherapy and Pharmacology
- 05 Oct 2013 New trial record